RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $76
RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:PCRX) with a Outperform and lowers the price target from $80 to $76.
Analyst Expectations for Pacira BioSciences’s Future
Analysts have provided the following ratings for Pacira BioSciences (NASDAQ:PCRX) within the last quarter: Bullish Somewhat Bullish Indifferent…
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $60
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $63 to $60.
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $60
BMO Capital analyst Gary Nachman maintains Pacira BioSciences (NASDAQ:PCRX) with a Market Perform and lowers the price target from $66 to $60.
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $74
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $76 to $74.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Needham Maintains Buy Rating for Pacira BioSciences: Here’s What You Need To Know
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00.
Shares of Pacira BioSciences are trading up 3.85% over the last 24 hours, at $53.47 per share.